Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 421

1.

Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC).

Spachmann PJ, Azzolina V, Weber F, Evert M, Eckstein M, Denzinger S, Burger M, Otto W, Breyer J.

Pathol Oncol Res. 2019 Sep 10. doi: 10.1007/s12253-019-00745-7. [Epub ahead of print]

PMID:
31506803
2.

[Tumor-suspected focal lesion on the renal hilus].

Kuhnen C, Otto W, Pützler M.

Pathologe. 2019 Sep;40(5):546-547. doi: 10.1007/s00292-019-0621-4. German.

PMID:
31240450
3.

Pediatric Mucormycosis: A 10-Year Systematic Review of Reported Cases and Review of the Literature.

Otto WR, Pahud BA, Yin DE.

J Pediatric Infect Dis Soc. 2019 Jun 10. pii: piz007. doi: 10.1093/jpids/piz007. [Epub ahead of print]

PMID:
31181136
4.

BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study.

Hutterer GC, Posch F, Buser L, Zigeuner R, Morshäuser L, Otto W, Wild PJ, Burger M, May M, Pichler M, Brookman-May SD.

Urol Oncol. 2019 Jul;37(7):510-518. doi: 10.1016/j.urolonc.2019.04.004. Epub 2019 May 3.

PMID:
31060796
5.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
6.

Impact of E-Cadherin and β-Catenin as Prognostic Factor in Renal Cell Carcinoma with Tumor Thrombus of the Vena Cava.

Spachmann PJ, Breyer J, Kalogirou C, Lausenmeyer EM, Weber F, Prohaska S, Denzinger S, Burger M, Kübler H, Otto W, Vergho D.

Urol Int. 2019;102(4):413-420. doi: 10.1159/000497279. Epub 2019 Mar 7.

PMID:
30844790
7.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B.

Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

8.

Microsatellite instability and manifestations of angiogenesis in stage IV of sporadic colorectal carcinoma.

Otto W, Macrae F, Sierdziński J, Smaga J, Król M, Wilińska E, Zieniewicz K.

Medicine (Baltimore). 2019 Jan;98(1):e13956. doi: 10.1097/MD.0000000000013956.

9.

Copper in Wood Preservatives Delayed Wood Decomposition and Shifted Soil Fungal but Not Bacterial Community Composition.

Lasota S, Stephan I, Horn MA, Otto W, Noll M.

Appl Environ Microbiol. 2019 Feb 6;85(4). pii: e02391-18. doi: 10.1128/AEM.02391-18. Print 2019 Feb 15.

10.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
11.

Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.

Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V.

Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9. Epub 2018 Nov 27.

PMID:
30483954
12.

Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer.

Lausenmeyer EM, Braun K, Breyer J, Gierth M, Denzinger S, Burger M, Voelker HU, Otto W.

Urol Int. 2019;102(1):77-82. doi: 10.1159/000493577. Epub 2018 Nov 1.

PMID:
30384365
13.

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.

Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P.

Int J Mol Sci. 2018 Oct 30;19(11). pii: E3396. doi: 10.3390/ijms19113396.

14.

Long-term effects and quality of life following definitive bile duct reconstruction.

Otto W, Sierdziński J, Smaga J, Dudek K, Zieniewicz K.

Medicine (Baltimore). 2018 Oct;97(41):e12684. doi: 10.1097/MD.0000000000012684.

15.

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P.

Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x.

16.

Improved prediction of nephron-sparing surgery versus radical nephrectomy by the optimized R.E.N.A.L. Score in patients undergoing surgery for renal masses.

Sterzik A, Solyanik O, Eichelberg C, Jost M, Graser A, Lausenmeyer EM, Otto W, Waidelich R, Stief CG, Burger M, May M, Brookman-May SD.

Minerva Urol Nefrol. 2019 Jun;71(3):249-257. doi: 10.23736/S0393-2249.18.03134-X. Epub 2018 Sep 24.

PMID:
30256079
17.

[Role of p16(INK4A) in detection of human papillomavirus DNA and stratification of cancer-specific mortality on the basis of long term follow-up data of 34 patients with invasive penile cancer].

Bründl J, Neppl C, Hommer T, Otto W, Breyer J, Brookman-May S, Weber F, Burger M, May M, Eichelberg C.

Aktuelle Urol. 2019 Sep;50(5):491-501. doi: 10.1055/a-0664-0316. Epub 2018 Sep 18. German.

PMID:
30227445
18.

Stage T1 bladder cancer: historic background and latest tracks for its demystification.

Otto W.

Transl Androl Urol. 2018 Aug;7(4):760-763. doi: 10.21037/tau.2018.06.13. No abstract available.

19.
20.

Expression, localisation and potential significance of aquaporins in benign and malignant human prostate tissue.

Bründl J, Wallinger S, Breyer J, Weber F, Evert M, Georgopoulos NT, Rosenhammer B, Burger M, Otto W, Rubenwolf P.

BMC Urol. 2018 Sep 3;18(1):75. doi: 10.1186/s12894-018-0391-y.

21.

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma.

Polifka I, Agaimy A, Herrmann E, Spath V, Trojan L, Stöckle M, Becker F, Ströbel P, Wülfing C, Schrader AJ, Barth P, Staehler M, Stief C, Hohenfellner M, Macher-Göppinger S, Wullich B, Noldus J, Brenner W, Roos FC, Walter B, Otto W, Burger M, Höfler H, Haferkamp A, Geppert CI, Stöhr C, Hartmann A; German Network Of Kidney Cancer.

Hum Pathol. 2019 Jan;83:212-223. doi: 10.1016/j.humpath.2018.08.006. Epub 2018 Aug 17.

PMID:
30121370
22.

FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.

Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W.

BJU Int. 2019 Jan;123(1):187-196. doi: 10.1111/bju.14525. Epub 2018 Sep 9.

PMID:
30120861
23.

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.

PMID:
29880460
24.

The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.

van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.

BJU Int. 2018 Dec;122(6):978-985. doi: 10.1111/bju.14238. Epub 2018 Apr 27.

PMID:
29637669
25.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

26.

High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany.

Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2.

PMID:
29525349
27.

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P.

Transl Oncol. 2018 Apr;11(2):467-476. doi: 10.1016/j.tranon.2018.02.001. Epub 2018 Feb 23.

28.

Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.

Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A.

Int J Urol. 2018 May;25(5):442-449. doi: 10.1111/iju.13532. Epub 2018 Feb 22.

29.

Differentiation-associated urothelial cytochrome P450 oxidoreductase predicates the xenobiotic-metabolizing activity of "luminal" muscle-invasive bladder cancers.

Baker SC, Arlt VM, Indra R, Joel M, Stiborová M, Eardley I, Ahmad N, Otto W, Burger M, Rubenwolf P, Phillips DH, Southgate J.

Mol Carcinog. 2018 May;57(5):606-618. doi: 10.1002/mc.22784. Epub 2018 Feb 1.

30.

p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models.

Morshaeuser L, May M, Burger M, Otto W, Hutterer GC, Pichler M, Klatte T, Wild P, Buser L, Brookman-May S.

Urol Oncol. 2018 Mar;36(3):94.e15-94.e21. doi: 10.1016/j.urolonc.2017.11.011. Epub 2017 Dec 6.

PMID:
29221641
31.

Serum metabolites and risk of myocardial infarction and ischemic stroke: a targeted metabolomic approach in two German prospective cohorts.

Floegel A, Kühn T, Sookthai D, Johnson T, Prehn C, Rolle-Kampczyk U, Otto W, Weikert C, Illig T, von Bergen M, Adamski J, Boeing H, Kaaks R, Pischon T.

Eur J Epidemiol. 2018 Jan;33(1):55-66. doi: 10.1007/s10654-017-0333-0. Epub 2017 Nov 27.

32.

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A.

Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17.

PMID:
29150702
33.

Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies.

Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A.

Oncotarget. 2017 Jun 28;8(40):67684-67695. doi: 10.18632/oncotarget.18804. eCollection 2017 Sep 15.

34.

Differential cellular metabolite alterations in HaCaT cells caused by exposure to the aryl hydrocarbon receptor-binding polycyclic aromatic hydrocarbons chrysene, benzo[a]pyrene and dibenzo[a,l]pyrene.

Potratz S, Jungnickel H, Grabiger S, Tarnow P, Otto W, Fritsche E, von Bergen M, Luch A.

Toxicol Rep. 2016 Sep 16;3:763-773. doi: 10.1016/j.toxrep.2016.09.003. eCollection 2016.

35.

Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer.

Breyer J, Shalekenov S, Aziz A, van Rhijn BWG, Bründl J, Lausenmeyer E, Schäfer J, Denzinger S, Giedl C, Burger M, Hartmann A, Evert M, Otto W.

Bladder Cancer. 2017 Jul 27;3(3):173-180. doi: 10.3233/BLC-170103.

36.

Clinical Markers and Outcomes of Neonates With Herpes Simplex Virus Deoxyribonucleic Acid Persistence in Cerebrospinal Fluid in Disseminated and Central Nervous System Infection.

Otto WR, Myers AL, LaRussa B, Kimberlin DW, Jackson MA.

J Pediatric Infect Dis Soc. 2018 May 15;7(2):e30-e33. doi: 10.1093/jpids/pix033.

PMID:
28510722
37.

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.

Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2017 Jul 18;8(29):47595-47606. doi: 10.18632/oncotarget.17394.

38.

[Clinical and pathological prognostic factors for the long-term survival of patients with pT1 renal cell carcinoma].

Breyer J, Otto W, Lausenmeyer EM, Denzinger S, Schwientek AK, Ochs L, Mayr R, Gierth M, Bründl J, Burger M, Evert M, Fritsche HM, Eichelberg C.

Aktuelle Urol. 2017 May;48(3):230-237. doi: 10.1055/s-0043-101725. Epub 2017 Apr 19. German.

PMID:
28423432
39.

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W.

Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22.

40.

Aquaporin 3 Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading?

Breyer J, Otto W, Burger M, Hartmann A, Rubenwolf PC.

Bladder Cancer. 2017 Jan 27;3(1):31-34. doi: 10.3233/BLC-160082.

41.

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.

Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10.

PMID:
28074276
42.

WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.

Otto W, Breyer J, Herdegen S, Eder F, Bertz S, May M, Mayr R, Lausenmeyer EM, Denzinger S, van Rhijn BW, Burger M, Hartmann A.

Int Urol Nephrol. 2017 Mar;49(3):431-437. doi: 10.1007/s11255-016-1491-9. Epub 2016 Dec 29.

PMID:
28035618
43.

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.

Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Urol Int. 2017;98(3):282-289. doi: 10.1159/000453670. Epub 2016 Dec 17.

PMID:
27992871
44.

Immunotherapy in urothelial carcinoma: fade or future standard?

Breyer J, Burger M, Otto W.

Transl Androl Urol. 2016 Oct;5(5):662-667. Review.

45.

ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W.

Virchows Arch. 2016 Nov;469(5):547-552. Epub 2016 Aug 11.

PMID:
27514658
46.

Biochemical Foundations of Health and Energy Conservation in Hibernating Free-ranging Subadult Brown Bear Ursus arctos.

Welinder KG, Hansen R, Overgaard MT, Brohus M, Sønderkær M, von Bergen M, Rolle-Kampczyk U, Otto W, Lindahl TL, Arinell K, Evans AL, Swenson JE, Revsbech IG, Frøbert O.

J Biol Chem. 2016 Oct 21;291(43):22509-22523. Epub 2016 Sep 8.

47.

Downregulation of Checkpoint Protein Kinase 2 in the Urothelium of Healthy Male Tobacco Smokers.

Breyer J, Denzinger S, Hartmann A, Otto W.

Urol Int. 2016;97(4):480-481. Epub 2016 Jun 2.

PMID:
27251560
48.

[More than just "stones" : On the history of urology in Regensburg].

Otto W.

Urologe A. 2016 Jul;55(7):974-80. doi: 10.1007/s00120-016-0114-5. German.

PMID:
27220891
49.

Large retroperitoneal pelvic low-grade mucinous neoplasia 25 years after pull-through operation for imperforate anus.

Bashirov A, Vieth M, Lang-Schwarz C, Kuhnen C, Fischer F, Otto W, Allemeyer EH.

Int J Colorectal Dis. 2016 Sep;31(9):1653-4. doi: 10.1007/s00384-016-2592-8. Epub 2016 May 3. No abstract available.

PMID:
27138641
50.

Metabotypes with properly functioning mitochondria and anti-inflammation predict extended productive life span in dairy cows.

Huber K, Dänicke S, Rehage J, Sauerwein H, Otto W, Rolle-Kampczyk U, von Bergen M.

Sci Rep. 2016 Apr 19;6:24642. doi: 10.1038/srep24642.

Supplemental Content

Support Center